WHERE IS THE VALUE CREATION Linda Tharby has been at the helm since April 2021. At that time the share price was about $3.5<>$3.75. The has been one public investor presentation 12/9/21 called ironically "Vision 2026 -next phase value creation".
.KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results, Accelerating to 19% Revenue Growth in 2022
Recent Highlights:
Fourth quarter net revenue growth of 13% to $7.3 million, marking the fifth consecutive quarter of double-digit growth, and full year net revenue growth of 19% to $27.9 million
Novel Therapies business finished the year with 14 total collaborations to date – growing pre-commercial revenue from $0.5 million in 2021 to $2.5 million for full year 2022
11% Core business growth (U.S. and International) for the year driven by overall SCIg market growth and market share gains through prefilled syringe adoptions
Improved cash position to $17.4 million ending the fourth quarter via strong working capital management
2023 net revenues expected to be between $32.5 and $33.5 million, representing growth in the range of 17-20%